Avilar Therapeutics Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Avilar Therapeutics

Access the complete profile.

Avilar Therapeutics Fast Facts

Revenue	$10 - $100 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	4242 Drugs & Druggists' Sundries Merchant Wholesalers
Address	400 Totten Pond Road Suite 110 Waltham, MA 02451

Note: Revenues for privately held companies are statistical evaluations.


Avilar Therapeutics's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Avilar Therapeutics's annual revenues are $10 - $100 million (see exact revenue data)
• What industry is the company in?
  • Avilar Therapeutics is classified as operating in the Drugs & Druggists' Sundries Merchant Wholesalers industry, NAICS Code 4242.

Avilar Therapeutics Annual Revenue and Growth Rate

Avilar Therapeutics	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$10 - $100 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Avilar Therapeutics's revenues are gauged from an analysis of company filings.

Avilar Therapeutics's Income Statement (based on Industry Averages)

Avilar Therapeutics P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Avilar Therapeutics is developing and marketing. Avilar Therapeutics doesn't have any recent trademark applications, indicating Avilar Therapeutics is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
XTAC Pharmaceutical preparations for the treatment of immunological, neurological, metabolic diseases mediated by extracellular proteins	02/11/2022
AVILAR THERAPEUTICS Pharmaceutical research and development	02/11/2022
MTAC Pharmaceutical preparations for the treatment of immunoglogical, neurological, and metabolic diseases mediated by extracellular proteins	11/23/2021

See all trademarks and details in the Full Report.

Market Share of Avilar Therapeutics's Largest Competitors

A competitive analysis shows these companies are in the same general field as Avilar Therapeutics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
AMERISOURCEBERGEN	Conshohocken, PA	100
MCKESSON	Irving, TX	58
CARDINAL HEALTH 119	Dublin, OH	42
TAKEDA PHARMACEUTICALS AMERICA	Lexington, MA	31
CATALENT PHARMA SOLUTIONS	Somerset, NJ	13
OWENS & MINOR DISTRIBUTION	Mechanicsville, VA	11
J M SMITH	Spartanburg, SC	3
DAIICHI SANKYO	Basking Ridge, NJ	3
HIKMA PHARMACEUTICALS USA	Berkeley Heights, NJ	2

Nearby Competitors

These companies are similar in business line and location to Avilar Therapeutics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
TAKEDA PHARMACEUTICALS AMERICA	Lexington, MA	100
SOBI	Waltham, MA	3
TRIANA BIOMEDICINES	Waltham, MA	0
AVILAR THERAPEUTICS	Waltham, MA	0
RESEARCH BLOOD COMPONENTS	Watertown, MA	0

Future Competition: Avilar Therapeutics's Fastest Growing Competitors

These companies are in the same general field as Avilar Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)